Quarterly A1c Monitoring: Clinical Situations, Not Specific Drugs
Quarterly A1c monitoring is not tied to specific medications but rather to clinical situations: patients not meeting glycemic goals, those with recent treatment changes, or experiencing frequent hypoglycemia or hyperglycemia—regardless of which diabetes medication they are taking 1, 2.
The Key Distinction
The question asks for a "list of drugs" requiring quarterly monitoring, but this reflects a fundamental misunderstanding of diabetes management guidelines. A1c monitoring frequency is determined by glycemic control status and treatment stability, not by the specific drug class prescribed 1, 2.
When Quarterly A1c Monitoring Is Indicated
According to the most recent 2025 ADA Standards of Care, assess glycemic status every 3 months for 1:
- Individuals not meeting their glycemic goals (typically A1c ≥7% for most adults)
- Patients with recent treatment changes (any medication adjustment, regardless of drug class)
- Those experiencing frequent or severe hypoglycemia or hyperglycemia
- Patients with changes in health status
- Periods of rapid growth and development in youth
When Less Frequent Monitoring Is Appropriate
Patients who have achieved and are maintaining glucose levels within their target range may only need A1c testing twice yearly 1, 2. This applies to stable patients on any diabetes regimen—whether metformin monotherapy, insulin, GLP-1 agonists, SGLT2 inhibitors, or combination therapy.
Clinical Application
The 2023 guidelines reinforce this approach: "at least quarterly and as needed in patients whose therapy has changed and/or who are not meeting glycemic goals" 2. This means:
- Starting any new diabetes medication → quarterly monitoring until stable
- Dose adjustments of existing medications → quarterly monitoring until goals achieved
- Poor control on current regimen → quarterly monitoring regardless of drug class
- Stable control achieved → can extend to every 6 months
Common Pitfall to Avoid
Do not assume certain "high-risk" medications automatically require quarterly monitoring while others don't. Even patients on insulin who are stable and at goal can be monitored every 6 months, while patients on metformin alone who are above target need quarterly checks 1, 2.